World TB Day: improving diagnosis and treatment. Despite being curable, tuberculosis (TB) remains endemic in much of the world. High rates of TB are often found in homeless populations, people in prison, people with drug abuse problems and those with other chronic conditions, such as HIV. Two new drugs have recently been licensed for multi-drug-resistant TB (MDR-TB) but the mainstay of first-line therapy comprises isoniazid, rifampicin, pyrazinamide and ethambutol, all of which can have debilitating side effects. Patients have to take a cocktail of some combination of these drugs for six months, which can lead to difficulties with compliance, especially if they have other, social, issues. World TB Day, held each year on 24 March, aims to raise public awareness of TB and urge governments to take action. This year's theme is 'Unite to end TB'.
Fluoroquinolones for treating tuberculosisSubscription
Tuberculosis (TB) remains a significant global health and socioeconomic challenge. The duration of current anti-TB therapies, the adverse effects of certain anti-TB drugs and the growing problem of drug-resistant TB on an international scale mean that it is imperative for new, effective and safe treatment regimens to be developed. Fluoroquinolones are a class of drugs that have been used in the treatment of TB for several decades. This article provides an overview of the current treatment ...
London has become the capital of Western Europe for tuberculosis, but an intensive focus on the disease and several new strategies are improving diagnosis and treatment.
Cephalosporins could boost anti-TB therapySubscription
Antimicrobial therapy for tuberculosis (TB) is hampered by the need for long treatment duration and rising prevalence of drug-resistant strains.
The World Health Organization (WHO) has published new recommendations that seek to speed up detection and enhance cure rates for patients with multidrug resistant tuberculosis (MDR-TB).
Incubating cells with turmeric compound reduced Mycobacterium tuberculosis infection.
Just 2% of people with multidrug-resistant tuberculosis have access to drugs that have been on the market for the past two years and which have the potential to save their lives, according to a report by charity Médecins Sans Frontières.
The upper age limit for treating adults with latent tuberculosis (TB) has been increased from 35 years to 65 years in updated guidelines released by the National Institute for Health and Care Excellence.
Over the past 15 years, pharmaceutical innovation, coupled with lower prices and improved access to essential medicines, has driven improvements in global health outcomes, says a World Health Organization report.
Progress has been made in the global fight against tuberculosis but serious gaps remain in the detection and treatment of the disease, says a World Health Organization report.
Researchers gave animals a modified version of the tuberculosis bacterium, which helped them fight off infection from disease-causing TB.
Georgia has become the first country to receive free courses of the anti-tuberculosis drug bedaquiline (Sirturo) through an innovative drug donation partnership between USAID and Janssen Therapeutics.
What’s been happening in the world of pharmacy? Here’s our pick of must-read news from the past month.